Study Says: Post-menopausal hormone therapy cuts heart disease

New York: A team of US researchers has found that hormone therapy, when taken within six years of menopause, may slow the progression of subclinical atherosclerosis -- the primary underlying pathway that leads to heart disease and stroke.

The findings suggest that after a median of five years of hormone therapy, women in the early post-menopausal group who were taking estradiol, showed significantly less rate of blocked arteries -- a condition that can lead to heart disease and stroke, when measured against those taking the placebo. 

"Studies on hormone therapy and vascular degeneration, provides strong evidence that the cardiovascular benefits of hormone therapy are dependent on timing of initiation," said Howard N. Hodis from Keck School of Medicine at the University of Southern California in the US.

The researchers examined the hypothesis that the cardiovascular effects of post-menopausal hormone therapy vary with the timing of hormone therapy initiation.

The team conducted a study, published in the New England Journal of Medicine, Early versus Late Intervention Trial with Estradiol (ELITE) in over 600 post-menopausal women with no history of cardiovascular disease or diabetes.

They were stratified into two groups: early post-menopause -- women who were within six years of menopause and late post-menopause -- women who were 10 years or more beyond menopause. 

Women in each group were randomly assigned to receive either oral estradiol -- with progesterone vaginal gel for those with a uterus or a placebo -- which included a placebo vaginal gel for those with a uterus. 

"ELITE provides proof of concept and first direct evidence from human investigation that timing of hormone therapy is imperative for success in the prevention of atherosclerosis progressio," Hodis added. 

"The stratification of participants into early and late post-menopause was a unique feature of ELITE. We believe that applying this design to further examination of heart disease prevention could ultimately prove immensely fruitful for women's health," Hodis noted.

The concept of timing of initiation of an intervention is likely applicable to most preventive approaches to cardiovascular disease in women, the authors stated.

For Women - Hormone therapy: Is it right for you?

Hormone therapy was once routinely used to treat menopausal symptoms and protect long-term health. Then large clinical trials showed health risks. What does this mean to you? By Mayo Clinic Staff

Hormone replacement therapy — medications containing female hormones to replace the ones the body no longer makes after menopause — used to be a standard treatment for women with hot flashes and other menopause symptoms. Hormone therapy (as it's now called) was also thought to have the long-term benefits of preventing heart disease and possibly dementia.

Use of hormone therapy changed abruptly when a large clinical trial found that the treatment actually posed more health risks than benefits for one type of hormone therapy, particularly when given to older postmenopausal women. As the concern about health hazards attributed to hormone therapy grew, doctors became less likely to prescribe it.

Hormone therapy is no longer recommended for disease prevention, such as heart disease or memory loss. However, further review of clinical trials and new evidence show that hormone therapy may be a good choice for certain women, depending on their risk factors. What are the benefits of hormone therapy?

The benefits of hormone therapy depend, in part, on whether you take systemic hormone therapy or low-dose vaginal preparations of estrogen.

Systemic hormone therapy. Systemic estrogen — which comes in pill, skin patch, gel, cream or spray form — remains the most effective treatment for relief of troublesome menopausal hot flashes and night sweats. Estrogen can also ease vaginal symptoms of menopause, such as dryness, itching, burning and discomfort with intercourse.

Although the Food and Drug Administration (FDA) still approves estrogen for the prevention of the bone-thinning disease called osteoporosis, doctors usually recommend medications called bisphosphonates to treat osteoporosis. Low-dose vaginal products. Low-dose vaginal preparations of estrogen — which come in cream, tablet or ring form — can effectively treat vaginal symptoms and some urinary symptoms, while minimizing absorption into the body. Low-dose vaginal preparations do not help with hot flashes, night sweats or protection against osteoporosis. Long-term systemic hormone therapy for the prevention of postmenopausal conditions is no longer routinely recommended. But some data suggest that estrogen can decrease the risk of heart disease when taken early in postmenopausal years.

A recent, randomized, controlled clinical trial — the Kronos Early Estrogen Prevention Study (KEEPS) — explored estrogen use and heart disease in younger postmenopausal women. The study found no significant association between hormone therapy and heart disease.

For women who haven't had their uterus removed, estrogen is typically prescribed along with progesterone or progestin (progesterone-like medication). This is because estrogen alone, when not balanced by progesterone, can stimulate growth of the lining of the uterus, increasing the risk of uterine cancer. Women who have had their uterus removed (hysterectomy) don't need to take progestin. What are the risks of hormone therapy?

In the largest clinical trial to date, a combination estrogen-progestin pill (Prempro) increased the risk of certain serious conditions, including:

• Heart disease
• Stroke
• Blood clots
• Breast cancer

A related clinical trial evaluating estrogen alone (Premarin) in women who previously had a hysterectomy found no increased risk of breast cancer or heart disease. The risks of stroke and blood clots were similar to the combination therapy.

Hormone therapy, particularly estrogen combined with a progestin, can make your breasts look more dense on mammograms, making breast cancer more difficult to detect. Also, especially when taken for more than a few years, hormone therapy increases the risk of breast cancer, a finding confirmed in multiple studies of different hormone therapy combinations, not just limited to a combination estrogen-progestin pill (Prempro).

The risks of hormone therapy may vary depending on whether estrogen is given alone or with a progestin, and depending on your current age and age at menopause, the dose and type of estrogen, and other health risks such as your risks of heart and blood vessel (cardiovascular) disease, cancer risks and family medical history.

All of these risks should be considered in deciding whether hormone therapy might be an option for you. Who should consider hormone therapy?

Despite the health risks, systemic estrogen is still the most effective treatment for menopausal symptoms. The benefits of hormone therapy may outweigh the risks if you're healthy and:

Experience moderate to severe hot flashes or other menopausal symptoms Have lost bone mass and either can't tolerate or aren't benefitting from other treatments Stopped having periods before age 40 (premature menopause) or lost normal function of your ovaries before age 40 (premature ovarian insufficiency) Women who experience an early menopause, particularly those who had their ovaries removed and don't take estrogen therapy until at least age 45, have a higher risk of:

• Osteoporosis
• Coronary heart disease
• Earlier death
• Parkinsonism (Parkinson's-like symptoms)
• Anxiety or depression

Early menopause typically lowers the risk of most types of breast cancer. For women who reach menopause prematurely, the protective benefits of hormone therapy usually outweigh the risks.

Your age, type of menopause and time since menopause play a significant role in the risks associated with hormone therapy. Talk with your Blueprint Patient Care Coordinator about it.